Boston Scientific Shares Positive Findings on Agent Drug-Coated Balloon
Boston Scientific shared findings from new analyses of its Agent drug-coated balloon (DCB), an alternative to traditional therapies like balloon angioplasty and stenting.
The paclitaxel-coated balloon transfers a therapeutic dose of drug to the vessel wall, helping to prevent in-stent restenosis (ISR) reoccurrence. The FDA approved the balloon in March 2024.
Study Findings
A prospective, non-randomized, multi-center registry used real-world data from the CathPCI registry, evaluating over 12,000 patients treated with the Agent DCB during a 2-year period (April 2024-June 2025) across more than 700 U.S. centers.
Christina Lalani presented the findings at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.
No direct quotes available in the text.
Author's summary: Boston Scientific shares positive findings on Agent DCB.
More News
- African tax leaders meet in Uganda to tackle effective taxation of the wealthy - Institute of Development Studies
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
- Emma Thompson Explodes in Rage Over the 'Intense Irritation' of AI: 'Will You F--k Off?!' | Video
- AI tool paints bigger picture of global impact of millions of research grants, papers and patents
- From proof of concept to powerhouse: Why federal agencies need AI factories
- Research ICT Africa develops AI framework for Africa
- Acclime Acquires Crowe Singapore to Create Regional Professional Services Powerhouse | AAP
- The FDA Withholds Names of Drugs Made in Contaminated Factories
- GSK secures rights to Syndivia’s ADC asset for prostate cancer
- The Renters’ Rights Act becomes Law: Securing a fairer future for 11 million renters